Market revenue in 2023 | USD 86.7 million |
Market revenue in 2030 | USD 131.4 million |
Growth rate | 6.1% (CAGR from 2023 to 2030) |
Largest segment | Phase iii |
Fastest growing segment | Phase I |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Phase I, Phase II, Phase III, Phase IV |
Key market players worldwide | Novartis AG ADR, Labcorp Holdings Inc, Medpace Holdings Inc, Charles River Laboratories International Inc, Icon PLC, GlaxoSmithKline Consumer Healthcare (GSK CH India), Aurora Innovation Inc Class A, Biogen Inc, IQVIA Holdings Inc, inVentiv Health |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to neurology clinical trials market will help companies and investors design strategic landscapes.
Phase iii was the largest segment with a revenue share of 46.14% in 2023. Horizon Databook has segmented the Japan neurology clinical trials market based on phase i, phase ii, phase iii, phase iv covering the revenue growth of each sub-segment from 2018 to 2030.
In Japan, there is a high percentage of population above 65 years of age. The European Parliment states that one in four people in the country is above the age of 65, and Japan was ranked first in countries having the highest share of geriatric population.
The high geriatric population in the country is expected to increase the prevalence of neurological disorders such as dementia, Alzheimer’s disease, and Parkinson’s disease. This is expected to boost the demand for neurology research in the country.
The research studies in the country are actively involved in developing a technologically advanced treatment for neurological disorders. For instance, in November 2018, the researchers of Kyoto University Japan used reprogrammed stem cells to treat Parkinson’s disease. Such research studies being conducted are expected to boost the market in Japan over the forecast period.
Horizon Databook provides a detailed overview of country-level data and insights on the Japan neurology clinical trials market , including forecasts for subscribers. This country databook contains high-level insights into Japan neurology clinical trials market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account